cancer
Dietary intervention and the utilization of D. dubosii offer potential insights for the treatment of brain tumor patients.
New funding boosts development of microbiome-based therapies for hereditary cancer risk, opening paths to alternatives beyond surgery.
With a strategic loan from the European Investment Bank, the French biotech doubles down on its mission to bring microbiome ecosystem therapies to market for patients battling blood cancers.
Targeting the gut microbiota could help predict, prevent or reduce chemotherapy-related toxicity.
Plant compounds and gut microbiota activity influence how cancer drugs work and should be considered in treatment.
Nanoparticle-based approaches are a promising strategy for treating colorectal cancer.
Genetic factors can influence tumor-associated microbes, offering insights into colorectal cancer progression and potential therapeutic targets.
Certain bile acids produced by gut microbes can interact with specific receptors in the body, influencing immune cells to fight tumors.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
